Enfortumab Vedotin and Stereotactic Radiation for Localized Bladder Cancer
Enfortumab Vedotin and Stereotactic Radiation for Localized Bladder Cancer
Recruiting · NCT06394570 · Registry updated 2026-09-30Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Enfortumab Vedotin and Stereotactic Radiation for Localized Bladder Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, neoplasm, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Recruiting | Phase 1 / Phase 2 | 2026-09-30 | NCT06394570 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Astellas Pharma Inc | 43 |
| University of Texas Southwestern Medical Center | 295 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| UT Southwestern Medical Center | Dallas | United States | 210 |